Winslow Evans & Crocker’s Charles River Laboratories CRL Stock Holding History

Winslow Evans & Crocker’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-8	Closed	-$2K	–	1180
2019 Q1	$2K	Buy	+8	New	+$1.05K	﹤0.01%	1125
2014 Q4	–	Sell	-70	Closed	-$4.18K	–	1318
2014 Q3	$4.18K	Buy	+70	New	+$4K	﹤0.01%	1136

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Winslow Evans & Crocker's CRL Position: Q2 2019 in Review

Winslow Evans & Crocker sold out of Charles River Laboratories (CRL) in Q2 2019, closing a stake of 8 shares — an estimated $2K sold.

Winslow Evans & Crocker first reported a position in CRL in Q3 2014 and held it in 2 quarters. The position peaked at $4.18K in Q3 2014. 405 funds tracked by Wall St. Rank hold CRL as of Q2 2019.

Winslow Evans & Crocker reported no remaining Charles River Laboratories position as of Q2 2019 after selling out during the quarter.
Winslow Evans & Crocker sold 8 Charles River Laboratories shares in Q2 2019, an estimated $2K.
Winslow Evans & Crocker first reported a position in Charles River Laboratories in Q3 2014 and held it in 2 quarters.
Winslow Evans & Crocker's Charles River Laboratories position peaked at $4.18K in Q3 2014.
405 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2019.

Based on Winslow Evans & Crocker's 13F filing for Q2 2019, filed 19 Jul 2019.